Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Valiant Laboratories IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2021 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 133  to  140 per share
Profile
Min Investment ₹140
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Valiant Laboratories Ltd is a pioneering company at the forefront of cutting-edge scientific research and innovation. Founded on a commitment to advancing knowledge and pushing the boundaries of possibility, Valiant Laboratories specializes in a diverse range of fields, including biotechnology, pharmaceuticals, materials science, and beyond. Driven by a passionate team of scientists, engineers, and researchers, Valiant Laboratories is dedicated to developing groundbreaking solutions to some of the world's most pressing challenges. With a strong emphasis on ethical practices, sustainability, and responsible innovation, the company aims to create products and technologies that positively impact society and the environment. Valiant Laboratories' unwavering pursuit of excellence has earned it a reputation as a trusted partner for academia, industry, and government agencies seeking to explore new frontiers in science and technology. As it continues to push boundaries, Valiant Laboratories remains committed to shaping a brighter, more innovative future for all. Read More

Basic Info

Face Value 10 per share

Price 133  to  140 per share

P/E (x) -280

Sales( Cr.) 133

PAT( Cr.) -2

EPS -0.5

Draft Prospectus

Exchange BSE-NSE

Promoter

Company Promoters

Shantilal Shivji Vora Santosh Shantilal Vora Dhanvallabh Ventures LLP (DVL)

Pre Issue Share Holding 100%

Post Issue Share Holding 40.44%

Listing Details:

Listing Price: 149.43220845792

Listing Gain: 6.31%

Current Price: 77.4

Gain On Issue: 77.4 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Sep 27, 2023
Closing Date Oct 03, 2023
Allotment Oct 04, 2023
Refund Oct 05, 2023
Delivery of Shares Oct 05, 2023
Listing Date Oct 06, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 105 14,700
Retail (Max) 13 1365 191,100
S-HNI (Min) 14 1470 205,800
S-HNI (Max) 68 7140 999,600
B-HNI (Min) 69 7245 1,014,300

Objective of the Issue

1. Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility). 2. Investment in VASPL for funding its working capital requirements. 3. General corporate purposes.

Issue

Category Nos Bid Bid (x)
QIB 5445000 113419350 20.8x
NII 1633500 120290940 73.6x
Retail 3811500 61212690 16.1x
EMP 0 0 0x
Total 10890000 324086400 29.8x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Valiant Laboratories Profit & Loss

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 334 182 133
Other Income 5 10 5
Total Income 339 192 139
Total Expenditure 299 190 138
Operating Profit 40 1 1
Interest 0 0 0
Depreciation 2 2 2
Exceptional Income / Expenses 0 0 0
Profit Before Tax 38 -1 -2
Provision for Tax 9 -1 1
Profit After Tax 29 0 -2
Adjustments 0 0 0
Profit After Adjustments 29 0 -2
Adjusted Earnings Per Share 8.3 0.1 -0.5

Valiant Laboratories Balance Sheet

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 100 237 234
Minority's Interest 0 0 0
Borrowings 59 75 104
Other Non-Current Liabilities 2 2 3
Total Current Liabilities 51 29 60
Total Liabilities 213 343 401
Fixed Assets 48 50 48
Other Non-Current Assets 14 67 160
Total Current Assets 151 226 193
Total Assets 213 343 401

Valiant Laboratories Cash Flow

#(Fig in Cr.) Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 1 12
Cash Flow from Operating Activities 56 2 1
Cash Flow from Investing Activities -55 -144 -53
Cash Flow from Financing Activities -1 152 45
Net Cash Inflow / Outflow -0 10 -7
Closing Cash & Cash Equivalent 1 12 5

Valiant Laboratories Ratios

# Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 8.27 0.07 -0.47
CEPS(Rs) 8.71 0.49 -0.02
DPS(Rs) 0 0 0
Book NAV/Share(Rs) 28.65 50.6 50.05
Core EBITDA Margin(%) 10.5 -4.62 -3.52
EBIT Margin(%) 11.5 -0.38 -1
Pre Tax Margin(%) 11.42 -0.42 -1.13
PAT Margin (%) 8.68 0.18 -1.65
Cash Profit Margin (%) 9.15 1.26 -0.08
ROA(%) 13.62 0.12 -0.59
ROE(%) 28.86 0.19 -0.93
ROCE(%) 24.01 -0.29 -0.4
Receivable days 96.82 134.62 161.25
Inventory Days 14.26 23.11 19.16
Payable days 62.43 79.77 104.79
PER(x) 0 1978.6 0
Price/Book(x) 0 2.67 1.42
Dividend Yield(%) 0 0 0
EV/Net Sales(x) 0.27 3.31 2.84
EV/Core EBITDA(x) 2.27 472.86 501.61
Net Sales Growth(%) 0 -45.48 -26.74
EBIT Growth(%) 0 -101.8 -93.34
PAT Growth(%) 0 -98.9 -788.74
EPS Growth(%) 0 -99.17 -788.43
Debt/Equity(x) 0.59 0.32 0.52
Current Ratio(x) 2.97 7.76 3.23
Quick Ratio(x) 2.71 7.41 3.16
Interest Cover(x) 151.32 -8.89 -7.63
Total Debt/Mcap(x) 0 0.12 0.36

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -27% 0% 0% 0%
Operating Profit CAGR 0% 0% 0% 0%
PAT CAGR 0% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -20% NA% NA% NA%
ROE Average -1% 9% 9% 9%
ROCE Average -0% 8% 8% 8%

Company Contact Information

Valiant Laboratories Ltd.

109, Udyog Kshetra, First Floor Mulund Goregaon Link Road Mulund (West)

IPO Lead Manager(s)

Valiant Laboratories Ltd.

Unistone Capital Pvt Ltd.

Registrar Info

Valiant Laboratories Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!